XM nie świadczy usług obywatelom Stanów Zjednoczonych.
A
A

Abbott


Wiadomości

Abbott must pay $495 million in premature infant formula trial, jury finds

UPDATE 4-Abbott must pay $495 million in premature infant formula trial, jury finds Adds information about the verdict in paragraph 4, comment in paragraph 5 and 8 By Brendan Pierson and Dietrich Knauth July 26 (Reuters) - A jury on Friday found that Abbott Laboratories' ABT.N specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $495 million in damages.
A

US JURY FINDS ABBOTT'S PREMATURE INFANT FORMULA CAUSED GIRL'S DISEASE, AWARDS MOTHER $400 MLN IN PUNITIVE DAMAGES

Abbott must pay $95 million in premature infant formula trial, jury finds By Brendan Pierson and Dietrich Knauth July 26 (Reuters) - A jury on Friday found that Abbott Laboratories' ABT.N specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $95 million in compensatory damages.
A

Dexcom plunges as revenue forecast cut spooks investors

UPDATE 4-Dexcom plunges as revenue forecast cut spooks investors Updates shares in paragraph 1-2 By Bhanvi Satija July 26 (Reuters) - Dexcom DXCM.O shares closed more than 40% lower on Friday after the glucose monitor maker slashed its annual revenue forecast due to the fallout from a salesforce revamp, prompting some analysts to question its long-term prospects .
A
S

Dexcom shares plunge after it cuts annual revenue forecast

UPDATE 3-Dexcom shares plunge after it cuts annual revenue forecast Adds background, details in paragraphs 1, 3-4 July 25 (Reuters) - Medical device maker Dexcom DXCM.O cut its annual revenue forecast on Thursday, blaming a restructuring of its sales team, fewer customers, and lower revenue from each customer, sending its shares plummeting 40 % in extended trading.
A

Abbott Issues Voluntary Medical Device Correction For A Small Number Of Freestyle Libre 3 Sensors In The U.S.

BRIEF-Abbott Issues Voluntary Medical Device Correction For A Small Number Of Freestyle Libre 3 Sensors In The U.S. July 24 (Reuters) - Abbott Laboratories ABT.N : ISSUES VOLUNTARY MEDICAL DEVICE CORRECTION FOR A SMALL NUMBER OF FREESTYLE LIBRE® 3 SENSORS IN THE U.S. CORRECTION IMPACTS A SMALL SUBSET OF FREESTYLE LIBRE 3 SENSORS FROM AMONG THOSE WITHIN THREE LOTS IN THE U.S.
A

Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices

REFILE-Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices Corrects day in first paragraph July 24 (Reuters) - Edwards Lifesciences EW.N missed second-quarter revenue estimates on W ednesday , hurt by lower-than-expected demand for its artificial heart valves. Shares of the California-based company were down 14.3% at $74.50 after the bell.
A
B

Boston Scientific raises annual profit forecast on heart devices demand

UPDATE 2-Boston Scientific raises annual profit forecast on heart devices demand Adds details on results and background in paragraphs 5-6 July 24 (Reuters) - Boston Scientific BSX.N raised its full-year profit forecast on Wednesday on the back of strong demand for its heart devices, sending the company's shares up 2% in premarket trading. Medical device makers have been benefiting from increased demand for heart procedures and non-urgent surgeries such as hip and knee replacements over the past
A

Street View: Abbott faces investor hesitation despite strong fundamentals

BUZZ-Street View: Abbott faces investor hesitation despite strong fundamentals ** Abbott Laboratories ABT.N raised its annual profit forecast on Thursday after its second-quarter earnings edged past Wall Street estimates on double-digit growth on sales of its glucose monitors and strong demand for heart devices. ** Average recommendation of 26 brok
A

Intuitive Surgical results beat on growing demand for surgical robots

Intuitive Surgical results beat on growing demand for surgical robots July 18 (Reuters) - Intuitive Surgical ISRG.O on Thursday beat estimates for second-quarter profit and revenue on growing demand for its surgical robots used in minimally invasive procedures, sending its shares up 6.7% after the bell. Investor expectations around medical device makers have grown lately on hopes of elevated demand for surgical procedures as people, especially older adults, opt for medical procedures deferred du
A

Abbott plans marketing push for glucose monitors beyond diabetes

Abbott plans marketing push for glucose monitors beyond diabetes By Leroy Leo and Puyaan Singh July 18 (Reuters) - Abbott Laboratories ABT.N will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring device, CEO Robert Ford said on Thursday.
A

Abbott Laboratories reports results for the quarter ended in June - Earnings Summary

Abbott Laboratories reports results for the quarter ended in June - Earnings Summary Abbott Laboratories ABT.N reported quarterly adjusted earnings of $1.14​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.08. The mean expectation of twenty two analysts for the quarter was for earnings of $1.10 per share.
A

Abbott raises profit forecast on strong medical device sales

UPDATE 3-Abbott raises profit forecast on strong medical device sales Adds analyst comment in paragraph 4, share movement in paragraph 3 and background on nutrition in paragraph 8 By Leroy Leo and Puyaan Singh July 18 (Reuters) - Abbott Laboratories ABT.N raised its annual profit forecast on Thursday after its second-quarter earnings edged past Wall Street estimates on double-digit growth in sales of its glucose monitors and strong demand for heart devices.
A

Abbott Q2 Adjusted EPS USD 1.14 Vs. IBES Estimate USD 1.1

BRIEF-Abbott Q2 Adjusted EPS USD 1.14 Vs. IBES Estimate USD 1.1 Jul 18 (Reuters) - Abbott Q2 EPS USD 0.74. outlook FY adjusted EPS USD 4.61-4.71 outlook FY EPS USD 3.3-3.4
A

Abbott raises annual profit forecast as strong medical device sales power quarterly beat

Abbott raises annual profit forecast as strong medical device sales power quarterly beat July 18 (Reuters) - Abbott Laboratories ABT.N raised its annual profit forecast on Thursday and beat Wall Street estimates for second-quarter earnings, buoyed by strong sales of its cardiac and diabetes devices. The company now expects a profit of $4.61 to $4.71 per share for the full year, compared with its prior forecast of $4.55 to $4.70. On an adjusted basis, quarterly profit of $1.14 per share beat anal
A

REUTERS NEWS SCHEDULE AT 10:00 a.m. GMT/ 6:00 a.m. ET

REUTERS NEWS SCHEDULE AT 10:00 a.m. GMT/ 6:00 a.m. ET Here are the top stories and upcoming coverage plans for Reuters text service as of 10:00 a.m. GMT/ 6:00 a.m. ET. For a full schedule of news and events, go to our editorial calendar on Reuters Connect . TOP STORIES GLOBAL EU-VONDERLEYEN/PARLIAMENT EU's von der Leyen vows defence push, climate continuity in bid for second term European Commission President Ursula von der Leyen vowed on Thursday to create a "European Defence Union" and to stay
A
C
N
N
A
M

TSMC steadies the chips, ECB and Netflix eyed

MORNING BID AMERICAS-TSMC steadies the chips, ECB and Netflix eyed A look at the day ahead in U.S. and global markets from Mike Dolan Another impressive earnings beat from Taiwan's chipmaking giant TSMC 2330.TW may help calm this week's tech stock rout, as the earnings season turns toward wobbly megacaps with an update from Netflix on Thursday - just as the European Central Bank meets.
A
A
C
D
E
G
N
N
U
A
G
J
U
U
U
F
U
M
S
T

What to Watch in the Day Ahead - Thursday, July 18

What to Watch in the Day Ahead - Thursday, July 18 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Netflix is expected to report a rise in revenue in the second quarter, helped by its password-sharing crackdown and demand for its ad-supported version.
A
C
N
M

U.S. STOCKS Synchrony Financial, Crypto Stocks, Industrial REITs

BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Crypto Stocks, Industrial REITs Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq tumbled more than 2% to a two-week low on Wednesday, pulled down as megacap chip and tech stocks fell on the prospect of tighter China-focused U.S.
A
C
E
I
M
N
X
U
U
Z

Some medical device makers rise, while others tip lower after J&J results

BUZZ-Some medical device makers rise, while others tip lower after J&J results ** Some medical device manufacturers rise after Johnson & Johnson's JNJ.N results, while others fall ** Zimmer Biomet ZBH.N rise 2.9% to $110.58, Medtronic MDT.N gain 2.45% to $80.01, Abbott ABT.N rise 2.10% to $104.90, Stryker SYK.N up 1.04% at $336.90 ** Shares of Intu
A
C
S
Z

J&J beats Wall St estimates on strong drug sales ahead of Stelara competition

CORRECTED-UPDATE 3-J&J beats Wall St estimates on strong drug sales ahead of Stelara competition Corrects paragraph 4 as J&J CFO did not suggest pending Stelara insurance contracts would be 'favorable' By Patrick Wingrove and Bhanvi Satija July 17 (Reuters) - Johnson & Johnson JNJ.N beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara .
A
S



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.